vs
NATURAL GAS SERVICES GROUP INC（NGS）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
NATURAL GAS SERVICES GROUP INC的季度营收约是REGENXBIO Inc.的1.5倍（$46.1M vs $30.3M），NATURAL GAS SERVICES GROUP INC净利率更高（8.9% vs -221.3%，领先230.2%），REGENXBIO Inc.同比增速更快（43.0% vs 13.5%），NATURAL GAS SERVICES GROUP INC自由现金流更多（$-20.7M vs $-52.8M）
南方公司燃气（原AGL资源）是入选财富美国500强的美国能源服务控股公司，总部位于佐治亚州亚特兰大。公司业务涵盖天然气分销、批发服务、零售业务及中游运营，是美国规模最大的天然气分销企业之一，通过旗下受监管分销子公司，为全美四个州约450万公用事业客户提供服务。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
NGS vs RGNX — 直观对比
营收规模更大
NGS
是对方的1.5倍
$30.3M
营收增速更快
RGNX
高出29.5%
13.5%
净利率更高
NGS
高出230.2%
-221.3%
自由现金流更多
NGS
多$32.1M
$-52.8M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $46.1M | $30.3M |
| 净利润 | $4.1M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 15.4% | -190.0% |
| 净利率 | 8.9% | -221.3% |
| 营收同比 | 13.5% | 43.0% |
| 净利润同比 | 43.2% | -31.2% |
| 每股收益（稀释后） | $0.32 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NGSRGNX
| Q4 25 | $46.1M | $30.3M | ||
| Q3 25 | $43.4M | $29.7M | ||
| Q2 25 | $41.4M | $21.4M | ||
| Q1 25 | $41.4M | $89.0M | ||
| Q4 24 | $40.7M | $21.2M | ||
| Q3 24 | — | $24.2M | ||
| Q2 24 | — | $22.3M | ||
| Q1 24 | — | $15.6M |
净利润NGSRGNX
| Q4 25 | $4.1M | $-67.1M | ||
| Q3 25 | $5.8M | $-61.9M | ||
| Q2 25 | $5.2M | $-70.9M | ||
| Q1 25 | $4.9M | $6.1M | ||
| Q4 24 | $2.9M | $-51.2M | ||
| Q3 24 | — | $-59.6M | ||
| Q2 24 | — | $-53.0M | ||
| Q1 24 | — | $-63.3M |
毛利率NGSRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率NGSRGNX
| Q4 25 | 15.4% | -190.0% | ||
| Q3 25 | 24.8% | -176.3% | ||
| Q2 25 | 24.0% | -296.3% | ||
| Q1 25 | 23.0% | 13.6% | ||
| Q4 24 | 14.9% | -242.1% | ||
| Q3 24 | — | -256.6% | ||
| Q2 24 | — | -251.3% | ||
| Q1 24 | — | -408.8% |
净利率NGSRGNX
| Q4 25 | 8.9% | -221.3% | ||
| Q3 25 | 13.3% | -208.3% | ||
| Q2 25 | 12.5% | -331.8% | ||
| Q1 25 | 11.7% | 6.8% | ||
| Q4 24 | 7.0% | -241.3% | ||
| Q3 24 | — | -246.3% | ||
| Q2 24 | — | -237.7% | ||
| Q1 24 | — | -405.4% |
每股收益（稀释后）NGSRGNX
| Q4 25 | $0.32 | $-1.30 | ||
| Q3 25 | $0.46 | $-1.20 | ||
| Q2 25 | $0.41 | $-1.38 | ||
| Q1 25 | $0.38 | $0.12 | ||
| Q4 24 | $0.22 | $-0.99 | ||
| Q3 24 | — | $-1.17 | ||
| Q2 24 | — | $-1.05 | ||
| Q1 24 | — | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $274.7M | $102.7M |
| 总资产 | $586.8M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资NGSRGNX
| Q4 25 | — | $230.1M | ||
| Q3 25 | — | $274.2M | ||
| Q2 25 | $325.0K | $323.3M | ||
| Q1 25 | $2.1M | $267.9M | ||
| Q4 24 | $2.1M | $234.7M | ||
| Q3 24 | — | $255.5M | ||
| Q2 24 | — | $290.4M | ||
| Q1 24 | — | $338.7M |
股东权益NGSRGNX
| Q4 25 | $274.7M | $102.7M | ||
| Q3 25 | $271.4M | $161.5M | ||
| Q2 25 | $266.2M | $213.7M | ||
| Q1 25 | $260.3M | $274.2M | ||
| Q4 24 | $255.1M | $259.7M | ||
| Q3 24 | — | $301.4M | ||
| Q2 24 | — | $348.3M | ||
| Q1 24 | — | $390.7M |
总资产NGSRGNX
| Q4 25 | $586.8M | $453.0M | ||
| Q3 25 | $562.3M | $525.2M | ||
| Q2 25 | $525.5M | $581.0M | ||
| Q1 25 | $501.7M | $490.9M | ||
| Q4 24 | $492.5M | $466.0M | ||
| Q3 24 | — | $519.1M | ||
| Q2 24 | — | $569.4M | ||
| Q1 24 | — | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $13.9M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $-20.7M | $-52.8M |
| 自由现金流率自由现金流/营收 | -44.8% | -174.0% |
| 资本支出强度资本支出/营收 | 74.9% | 1.7% |
| 现金转化率经营现金流/净利润 | 3.38× | — |
| 过去12个月自由现金流最近4个季度 | $-58.6M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流NGSRGNX
| Q4 25 | $13.9M | $-52.3M | ||
| Q3 25 | $16.8M | $-56.0M | ||
| Q2 25 | $11.0M | $-49.3M | ||
| Q1 25 | $21.3M | $33.6M | ||
| Q4 24 | $9.4M | $-31.6M | ||
| Q3 24 | — | $-40.5M | ||
| Q2 24 | — | $-45.5M | ||
| Q1 24 | — | $-55.5M |
自由现金流NGSRGNX
| Q4 25 | $-20.7M | $-52.8M | ||
| Q3 25 | $-25.1M | $-56.5M | ||
| Q2 25 | $-14.8M | $-49.7M | ||
| Q1 25 | $2.0M | $32.6M | ||
| Q4 24 | $-5.1M | $-32.7M | ||
| Q3 24 | — | $-40.9M | ||
| Q2 24 | — | $-46.0M | ||
| Q1 24 | — | $-56.0M |
自由现金流率NGSRGNX
| Q4 25 | -44.8% | -174.0% | ||
| Q3 25 | -57.7% | -189.9% | ||
| Q2 25 | -35.8% | -232.8% | ||
| Q1 25 | 4.9% | 36.6% | ||
| Q4 24 | -12.6% | -154.2% | ||
| Q3 24 | — | -168.9% | ||
| Q2 24 | — | -206.2% | ||
| Q1 24 | — | -358.5% |
资本支出强度NGSRGNX
| Q4 25 | 74.9% | 1.7% | ||
| Q3 25 | 96.5% | 1.7% | ||
| Q2 25 | 62.4% | 1.8% | ||
| Q1 25 | 46.5% | 1.2% | ||
| Q4 24 | 35.8% | 5.1% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | — | 2.1% | ||
| Q1 24 | — | 3.6% |
现金转化率NGSRGNX
| Q4 25 | 3.38× | — | ||
| Q3 25 | 2.90× | — | ||
| Q2 25 | 2.12× | — | ||
| Q1 25 | 4.38× | 5.53× | ||
| Q4 24 | 3.29× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NGS
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
